Morgan Stanley’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Morgan Stanley’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,005	Closed	-$10K	–	8264
2022 Q1	$10K	Sell	3,005 -1,070	-26%	-$3.08K	﹤0.01%	7423
2021 Q4	$12K	Sell	4,075 -45	-1%	-$168	﹤0.01%	7431
2021 Q3	$16K	Buy	4,120 +3,728	+951%	+$19.2K	﹤0.01%	7186
2021 Q2	$2K	Buy	392 +69	+21%	+$488	﹤0.01%	7569
2021 Q1	$4K	Sell	323 -3,427	-91%	-$48.7K	﹤0.01%	7186
2020 Q4	$55K	Buy	3,750 +3,000	+400%	+$38.2K	﹤0.01%	6137
2020 Q3	$9K	Buy	+750	New	+$9.61K	﹤0.01%	6318

Morgan Stanley's CMPI Position: Q2 2022 in Review

Morgan Stanley sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 3,005 shares — an estimated $10K sold.

Morgan Stanley first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $55K in Q4 2020. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Morgan Stanley reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Morgan Stanley sold 3,005 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $10K.
Morgan Stanley first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Morgan Stanley's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $55K in Q4 2020.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Morgan Stanley's 13F filing for Q2 2022, filed 15 Aug 2022.